Jury Awards Alabama $215M In Lawsuit That Claimed AstraZeneca Overcharged Medicaid
Main Category: Medicare / Medicaid / SCHIPAlso Included In: Pharma Industry / Biotech Industry; Litigation / Medical Malpractice
Article Date: 25 Feb 2008 - 7:00 PDT
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
4 (1 votes) |
An Alabama state court jury has decided that AstraZeneca must pay the state $215 million after finding that the company charged the state's Medicaid program inflated prescription drug prices, Bloomberg/Philadelphia Inquirer reports. The Montgomery County Circuit Court jury in Montgomery, Ala., found AstraZeneca liable for misrepresentation and fraudulent concealment. The award includes $40 million in compensatory damages and $175 million in punitive damages (Bloomberg/Philadelphia Inquirer, 2/22).
Alabama Attorney General Troy King (R) in 2005 filed lawsuits against more than 70 pharmaceutical companies over Medicaid drug prices. The AstraZeneca case was the first to go to trial. The state has settled cases with Takeda Pharmaceuticals North America and DEY. Drug makers are required by federal law to give Medicaid the best price for drugs they offer to any customer. Montgomery attorney Jere Beasley, who represented the state, told the jury that AstraZeneca did not provide Alabama with "honest and accurate" prices for its drugs.
AstraZeneca says it obtained for the state the best prices it could (AP/Wall Street Journal, 2/22). In a statement, the company said, "AstraZeneca believes this lawsuit is legally and factually unfounded, and we intend to appeal to the Alabama Supreme Court if the trial court does not reject the jury's verdict" in a post-trial order (Bloomberg/Philadelphia Inquirer, 2/22). Tom Christian, a lawyer who represented AstraZeneca, said the prices the company charged the state were barely enough for pharmacists to stay in business. According to Christian, a large judgment that requires the company to lower prices would make it financially impossible for pharmacists to fill prescriptions for Medicaid beneficiaries (AP/Wall Street Journal, 2/22).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our medicare / medicaid / schip section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/98310.php>
APA
http://www.medicalnewstoday.com/releases/98310.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.





